About

Dr. Daniel Gilmer serves as the U.S. Paxlovid Launch Lead at Pfizer managing launch operations across all customer group workstreams and preparation for the expected transition from emergency use authorization to NDA approval.

He previously served as the global Commercial Development Lead for Pfizer's Rheumatology pipeline, including the anti-Interferon beta program. Dr. Gilmer joined Pfizer as a Director within Worldwide R&D and Medical (WRDM) Operations leading several strategic initiatives including the WRDM Op Plan, Project Lightspeed 2.0, and the WRDM Annual Review/ESG narrative. Prior to joining Pfizer, Dr. Gilmer worked for several years at McKinsey, where he led teams to deliver on commercial growth strategies and operational excellence. Dr. Gilmer has a Ph.D. in Biology from The Rockefeller University, where he researched novel approaches to treat antibiotic-resistant bacteria. From this work, he is an equal co-inventor on the patent for Exebacase (aka, CF-301 or PlySs2), licensed by ContraFect Corp., and developed through Phase 3. He completed a post-Baccalaureate research fellowship at the National Cancer Institute, National Institutes of Health, after earning a Bachelor of Science in Biology from Howard University. Dr. Gilmer enjoys good audiobooks, fun puzzles, and frequent bike rides.